Parkinson's disease (PD) is amongst the most frequent neurodegenerative disorders, the
main pathologic hallmark of which is the degeneration of the substantia nigra pars …

Thiazolidinedione (TZD) class of peroxisome proliferator receptor gamma (PPAR-γ) agonists
display neuroprotective effects in experimental Parkinson's disease (PD) models. Neurons …

Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized
by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) …

Parkinson's disease (PD) is a progressive and chronic neurodegenerative disorder,
characterized by progressive loss of dopaminergic neurons in substantia nigra. The etiology …

The peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated
transcriptional factor that belongs to the nuclear hormone receptor superfamily. PPARγ was …

Rosiglitazone is a commonly prescribed insulin‐sensitizing drug with a selective agonistic
activity on the peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ). PPAR‐γ can …

A dysregulated response of the neuroimmune system is a main contributor to the
progression of neurodegeneration in Parkinson's disease (PD). Recent findings suggest that …

Peroxisome proliferator-activated receptor (PPAR) γ is a potential pharmacological target for
disease-modification in Parkinson's disease (PD), mainly acting by modulating the …

Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to provide
neuroprotection in a number of neurodegenerative diseases including Parkinson's disease …

Peroxisome proliferator-activated receptor gamma (PPAR-γ) is one of the ligand-activated
transcription factors which regulates a number of central events and considered as a …